JP2024546803A - 選択的Ｔｒｅｇ刺激剤ＲＵＲ２０ｋＤ－ＩＬ－２及び関連組成物の投与計画 - Google Patents

選択的Ｔｒｅｇ刺激剤ＲＵＲ２０ｋＤ－ＩＬ－２及び関連組成物の投与計画 Download PDF

Info

Publication number
JP2024546803A
JP2024546803A JP2024534714A JP2024534714A JP2024546803A JP 2024546803 A JP2024546803 A JP 2024546803A JP 2024534714 A JP2024534714 A JP 2024534714A JP 2024534714 A JP2024534714 A JP 2024534714A JP 2024546803 A JP2024546803 A JP 2024546803A
Authority
JP
Japan
Prior art keywords
weeks
dose
once
respegaldesleukin
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546803A5 (https=
Inventor
アリ アシュラフザーデ，
スティーブン ウィット ドッド，
キンバリー アン ジャクソン，
ステイシー マサアキ カネシロ，
ポール アラン クレコティカ，
ブライアン レスリー コツィン，
カーステン シュミッツ，
ジョナサン ザレフスキー，
Original Assignee
ネクター セラピューティクス
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス, イーライ リリー アンド カンパニー filed Critical ネクター セラピューティクス
Publication of JP2024546803A publication Critical patent/JP2024546803A/ja
Publication of JP2024546803A5 publication Critical patent/JP2024546803A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024534714A 2021-12-14 2022-12-14 選択的Ｔｒｅｇ刺激剤ＲＵＲ２０ｋＤ－ＩＬ－２及び関連組成物の投与計画 Pending JP2024546803A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163289371P 2021-12-14 2021-12-14
US63/289,371 2021-12-14
US202263323126P 2022-03-24 2022-03-24
US63/323,126 2022-03-24
US202263325923P 2022-03-31 2022-03-31
US63/325,923 2022-03-31
US202263343505P 2022-05-18 2022-05-18
US63/343,505 2022-05-18
US202263374632P 2022-09-06 2022-09-06
US63/374,632 2022-09-06
PCT/US2022/081541 WO2023114833A1 (en) 2021-12-14 2022-12-14 Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Publications (2)

Publication Number Publication Date
JP2024546803A true JP2024546803A (ja) 2024-12-26
JP2024546803A5 JP2024546803A5 (https=) 2025-12-23

Family

ID=85157281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534714A Pending JP2024546803A (ja) 2021-12-14 2022-12-14 選択的Ｔｒｅｇ刺激剤ＲＵＲ２０ｋＤ－ＩＬ－２及び関連組成物の投与計画

Country Status (9)

Country Link
US (1) US20250049934A1 (https=)
EP (1) EP4447995A1 (https=)
JP (1) JP2024546803A (https=)
KR (1) KR20240123817A (https=)
AU (1) AU2022414070A1 (https=)
CA (1) CA3239501A1 (https=)
IL (1) IL313567A (https=)
MX (1) MX2024007345A (https=)
WO (1) WO2023114833A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
BR112020021564A2 (pt) 2018-05-21 2021-03-02 Nektar Therapeutics estimulador de treg seletivo rur20kd-il-2 e composições relacionadas
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
CA3119439A1 (en) 2018-11-09 2020-05-14 Regenex LLC Treatment method for graft-versus-host disease
CA3122843A1 (en) 2018-12-12 2020-06-18 The Brigham And Women's Hospital, Inc. Compositions and methods for immunosuppression
EP4150060A4 (en) 2020-05-13 2024-06-19 Rapa Therapeutics, LLC TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT)

Also Published As

Publication number Publication date
AU2022414070A1 (en) 2024-05-16
IL313567A (en) 2024-08-01
KR20240123817A (ko) 2024-08-14
WO2023114833A9 (en) 2023-09-21
US20250049934A1 (en) 2025-02-13
MX2024007345A (es) 2024-09-30
CA3239501A1 (en) 2023-06-22
EP4447995A1 (en) 2024-10-23
WO2023114833A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US20190002575A1 (en) Method for the treatment of multiple sclerosis
CN106794255A (zh) 使用针对cd28的域抗体治疗系统性红斑狼疮的方法
Yadav et al. Recombinant T‐Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double‐Blind, Placebo‐Controlled, Phase 1, Dose‐Escalation Study
Qasem et al. Therapeutic advancements in the management of psoriasis: a clinical overview and update
EP3703753A1 (en) Treating ige-mediated allergic diseases
US20250049934A1 (en) DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
US12454573B2 (en) Dosages of emactuzumab
CN118475363A (zh) 选择性treg刺激剂rur20kd-il-2及相关组合物的给药方案
Jilma et al. Demonstration of clinical comparability of the biosimilar filgrastim to Neupogen, in terms of safety and efficacy, in healthy volunteers and patients receiving myelosuppressive chemotherapy
US20250059289A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
US20240148827A1 (en) Methods and Compositions for Treatment of Disease
US11352421B2 (en) Treatment for adverse immune reaction to metal implant debris
WO2025179012A1 (en) Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
HK40062612A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2025029873A9 (en) Treatment of hair-loss disorder
KR20260026080A (ko) 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
Yadav et al. Clinical Study Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study
CN117337189A (zh) 用于治疗疾病的方法和组合物
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
HK1157192A (en) Method for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251215